MIPSS70 Prognostic Score System

Loading...

References

  1. Damien Luque Paz. Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.. Blood advances, 2025
  2. Hélène Pasquer. Current myeloproliferative neoplasm scoring systems for clinical practice.. Blood, 2025
  3. Matteo Guerra. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM. American Journal of Hematology, 2024
  4. G. G. Loscocco. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. American Journal of Hematology, 2023
  5. N. Gagelmann. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.. Blood, 2019
  6. H. Ali. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.. Blood advances, 2019
  7. P. Guglielmelli. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017
  8. N M Kröger. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.. Leukemia, 2015